Google Search Trends to assess public interest in and concern about Vuity for treating presbyopia.

Autor: Wakabayashi T; Wills Eye Hospital, Mid Atlantic Retina, Thomas Jefferson University, Philadelphia, Pennsylvania, United States of America., Mansour HA; Wills Eye Hospital, Mid Atlantic Retina, Thomas Jefferson University, Philadelphia, Pennsylvania, United States of America., Abishek RM; Wills Eye Hospital, Mid Atlantic Retina, Thomas Jefferson University, Philadelphia, Pennsylvania, United States of America., Sridhar J; Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida, United States of America., Cohen MN; Wills Eye Hospital, Mid Atlantic Retina, Thomas Jefferson University, Philadelphia, Pennsylvania, United States of America., Xu D; Wills Eye Hospital, Mid Atlantic Retina, Thomas Jefferson University, Philadelphia, Pennsylvania, United States of America., Deaner J; Wills Eye Hospital, Mid Atlantic Retina, Thomas Jefferson University, Philadelphia, Pennsylvania, United States of America., Yonekawa Y; Wills Eye Hospital, Mid Atlantic Retina, Thomas Jefferson University, Philadelphia, Pennsylvania, United States of America., Hsu J; Wills Eye Hospital, Mid Atlantic Retina, Thomas Jefferson University, Philadelphia, Pennsylvania, United States of America., Kuriyan AE; Wills Eye Hospital, Mid Atlantic Retina, Thomas Jefferson University, Philadelphia, Pennsylvania, United States of America.
Jazyk: angličtina
Zdroj: PloS one [PLoS One] 2023 Oct 26; Vol. 18 (10), pp. e0293066. Date of Electronic Publication: 2023 Oct 26 (Print Publication: 2023).
DOI: 10.1371/journal.pone.0293066
Abstrakt: Purpose: To assess public awareness, interest, and concerns regarding Vuity (1.25% pilocarpine hydrochloride ophthalmic solution), an eye drop for the treatment of presbyopia, based on Google Trends.
Methods: We used Google Trends that provides a relative search volume for queried terms, to evaluate searches for Vuity from June 30, 2021, to June 30, 2022, in the United States. The data for this study were downloaded on June 30, 2022. Main outcome measures were changes in relative search volumes for the terms "Vuity," "Eye drops for reading," "Eye drops for near vision," "Presbyopia," "Pilocarpine," and related popular search terms, such as "Vuity side effects," and "Vuity retinal detachment".
Results: Since the approval of Vuity on October 29, 2021, notable increases in the relative search volumes occurred for Vuity in October 2021, December 2021, and from March to April 2022, which coincided with its approval, availability, and subsequent direct-to-consumer advertising based on positive results of clinical trials. The direct-to-consumer advertising had the greatest impact on the search volume for Vuity. Specific interests included Vuity cost, where to buy it, and its side effects. Retinal detachment was the most highly searched Vuity side effect. Geographic variation was evident, with the relative search volumes highest for "Vuity" in Wyoming, followed by North Dakota.
Conclusion: Google Trends is a useful tool for monitoring increases in public interest in Vuity for presbyopia. Public concerns regarding side effects warrant further real-world investigations of the causal relationship between Vuity and retinal detachment.
Competing Interests: I have read the journal’s policy and the authors of this manuscript have the following competing interests: AEK: Consultant/Speaker: Alimera Sciences, Allergan, Bausch + Lomb, Eyepoint Pharmaceuticals, Optos, Novartis, Genentech/Roche, Recens Medical, Spark Therapeutics; Grant funding: Adverum, Annexon, Alcon Laboratories, Genentech/Roche. YY: Consultant/Advisory Board: Alcon, Bausch Health, Regeneron, Tarsus, Versant Health. JS: Consultant for Alcon, Apellis, DORC, Genentech/Roche, Regeneron, MNC: Consultant/Advisory Board: Allergan, Keeler, Apellis, Alimera Sciences, DX: Consultant for Gyroscope Therapeutics, Apellis, Bausch & Lomb. The competing interests do not alter our adherence to PLOS ONE policies on sharing data and materials.
(Copyright: © 2023 Wakabayashi et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje